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Abstract 
Objectives and aim:  Partial adherence with antipsychotic medications increases the relapse 
rate in patients with schizophrenia. The aim of the present study is to assess the frequency of 
and factors contributing to partial adherence.                                                                                              
Method: During May 2012, psychiatrists working in a psychiatric hospital in Amman- Jordan 
were asked to participate in a compliance study. They were requested to evaluate the 
compliance of patients with schizophrenia using a questionnaire consisting of 11 questions. 
The frequency of unintentional and intentional partial adherence as well as patient-related 
factors contributing to relapse was assessed. Demographic data of participants were collected 
and the responses of patients were analyzed using descriptive statistics.                                                                                 
Results: The psychiatrists regarded 74%of the evaluated patients as unintentionally partially 
adherent, 40% of the patients were intentionally partially adherent with medication 
throughout the study period. The most frequently assessed patient-related factors contributing 
to partial adherence were denial of illness (80%),lack of  or insufficient information about 
their disease and medication(74.9%/73.7%),needing someone to remind  them to take their 
medication(74.3%), side-effects related causes (64.8%), the cost of medication ( 63.1%), and 
long duration and complexity of regimen(60.9%). 
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Backgrounds and literature 
Schizophrenia is a severe psychiatric (Garzya, et al., 2007) chronic and disabling 
illness (Kazadi et al., 2003) that has around 1% lifetime risk and affects young age group. 
Half of those individuals, their illness will be lifelong, probably requiring long-term 
medication (Lean et al., 2003) and has a life time prevalence of 4.0/1000 individuals 
worldwide (Stip et al., 2010) and 0.7% in the united state with serious physical, social and 
economic consequences (Csernansky et al., 2002) which is often accompanied by relapse 
even while on treatment (Kazadi et al., 2003). Prevention of relapse is a major goal of 
maintenance treatment in patients with psychotic disorders (Csernansky et al., 2002). Certain 
criteria are used to define relapse that includes aggravation of positive or negative symptoms, 
hospital admission in past months, and intensive case management and/or change in 
medication (Kazadi et al., 2003). Relapse may result in hospitalization, treatment resistance, 
cognitive impairment, and personal distress, extra costs by health providers, incarceration and 
inference with rehabilitation efforts (Kazadi et al., 2003). Diagnostic features of 
schizophrenia include positive symptoms (hallucinations(Garzya et al.,2007), delusions, 
disorganized thoughts (stip et al.,2010;Garzya et al.,2007;Caepenter,2010) and behavior (stip 
et al.,2010;Caepenter,2010)), negative symptoms (loss of motivation(stip et al.,2010;Garzya 
et al.,2007), social withdrawal(Garzya et al.,2007), affective flattening, restricted emotional 
experience and expression, poverty of speech, reduced hedonic capacity(Stip et al., 2010) ) 
and cognitive dysfunction symptomatic of the illness having persistent negative impact on 
patient ability to maintain relationships and engage in productive work in addition to 
disorganized thinking and memory impairments(Garzya et al.,2007). Any of those elements 
of the illness in theory reduces the capacity to make decisions (Caepenter, 1999). There is 
evidence that more than 90% of patients with schizophrenia have sleep problems. Sleep 
problems may exacerbate existing psychopathology by causing, distress and other negative 
effects on psychosocial rehabilitation and general functioning (Dursun et al., 1999).   
Internationally, the factors commonly associated with relapse include poor adherence 
treatment –which is thought to be the most crucial issue, substance abuse (Kazadi et al., 
2003), co-morbid psychiatric illness, co-morbid medical and/or surgical condition, stressful 
life events (Weiden, 1997), and treatment setting (Kazadi et al., 2003). The medication 
compliance for psychiatric illness is 58%. More specifically, about half of the patients with 
schizophrenia are non-adherent to treatment. This non-adherence may be due to factors that 
are patient-related (e.g. substance abuse, forgetfulness, anxiety about side-effects, inadequate 
knowledge, lack of insight , lack of motivation, fear of stigma); health care-related (e.g. poor 
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patient/health care provider  relationship, poor services and access to services, and poor staff 
training); socio-economically related (e.g. illiteracy, low level of education) or treatment-
related (e.g. polypharmacology, complex treatment regimens)(Kazadi et al., 2003).The 
number of individuals in the population receiving antipsychotic drugs that have been grouped 
into older and newer classes(Maguire et al., 2002 )is surprisingly high(Lean, et al , 2003) and 
most of whom  treated with these antipsychotic medications are unmarried and unemployed, 
and may live with persistent psychotic and negative symptoms and cognitive 
impairments(Stover et al., 2008).  The compliance is often assessed by subjective or indirect 
methods such as patient self-report, care provider reports, other significant report and chart 
view, whereas direct objective methods, such as pill count, blood or urine analysis, electronic 
monitoring and electronic refill records are used infrequently (Rummel-Kluge et al., 2008). 
The degree to which an individual follows medical advice is a major concern in every 
medical specialty (Mitchell et al., 2007). 
Much attention has focused on methods to persuade patients to adhere to 
recommendations, without sufficient acknowledgement that avoidance of sometimes 
complex, costly and unpleasant regimens may be entirely rational (Mitchell et al., 2007). 
Numerous studies demonstrated that inadequate compliance and non persistence with 
prescribed medication regimens result in increased morbidity and mortality from a wide 
variety of illness, as well as increased health care costs (Cramer et al., 2008 ). Preventing 
rehospitalization of schizophrenia patients, the identified modifiable factors suggest further 
need for development and implementation of integrated mental health services in the 
community (Suzuki et al., 2003). The term ‘compliance’, ‘adherence’ and ‘concordance’ are 
not used consistently in the literature; some authors use them synonymously (Rummel-Kluge 
et al., 2008) whereas others define compliance (adherence: synonym) (Cramer et al., 2008) as 
the extent to which person complies with medication (Rummel-Kluge et al., 2008) in 
accordance with the prescribed interval, dose and dosing regimen (Hughes et al., 2007). On 
the other hand, concordance is defined as a wider concept, including habits and attitudes 
towards therapeutic strategies (Rummel-Kluge et al., 2008). Medication persistence may be 
defined as “the duration of time from initiation to discontinuation of therapy (Cramer et al., 
2008), non-compliance is a major problem in schizophrenia (Rummel-Kluge et al., 2008). 
The aim of the present study is to provide data on the frequency of partial adherence 
in patients with schizophrenia and to identify patient-related factors, among patients with 
schizophrenia that may be contributing to medication relapses.    
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Methods                                                                                                                                                                                                                               
During 14 days period in May 2012, psychiatrists and registered nursing working in a 
psychiatric hospital in Amman were asked to participate in this study. The participating 
physicians were requested to anonymously evaluate the compliance in patients with 
schizophrenia diagnosed according to ICD10, using a questionnaire consisting of 11 
questions (question A-K, possible answers were ‘yes’ or ‘no’; Table 1). The term 
‘compliance’ in the present study was defined as the extent to which a person complies with 
the prescribed medication.                                                                                                                                                                                                                                                    
 Question A asked about the patient’s negligence of taking his medicine due of 
dissatisfaction or denial of illness. Question B asked about patient’s negligence and 
intentional discontinuation of prescribed medication because he is convinced that there are 
other ways to treatment such as spiritual or Para-medical treatment. Questions C-H evaluated 
the patient-related factors contributing to partial compliance; questions C, D and E are related 
to patient’s negligence due to inadequate ideas about his illness or lack of knowledge about 
his medicine and the medication side-effect, whereas question F is related to concerns 
regarding cognitive problem or addiction to the medicine. Questions G and H are related to 
complex and costly treatment regimens related to intentional partial compliance due to  
Living conditions and fear from stigma, and satisfaction of recovering due to 
symptoms disappearance. Question K assessed the frequency of partial compliance because 
the physicians suspected that the patients had forgotten unintentionally to take their 
medication once or more during the past month. 
The participating physicians 
 A total of 12 psychiatrists and 35 registered nurses had been asked to participate, 
using the questionnaire and data were included in the analysis. All participants are working in 
Marka psychiatric hospital which is affiliated to Royal Medical Services in Jordan, 6 
psychiatrists ( 2 of them are consultants in the psychiatry department ,  two senior specialists 
and two specialists), 6 third year resident psychiatrists, and 35 nurses ( 6 of them are 
specialists psychiatric nurse and the rest are trained psychiatric practical nurse ).  
Statistical analysis 
Several statistical measures were used such as the arithmetic mean, T-test, Cronbach's 
Alpha test, and standard deviation. As for the standard of paragraph or question acceptance, 
the arithmetic mean should be greater than (0.5), and to be of a significant value, T must be 
greater than the tabular value or the significance level be less than 0.05. 
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Results 
All participants completed the patient’s compliance assessment; data on the 
assessment of compliance are, therefore, available for 179 patients with schizophrenia (Table 
1). 29 patients are not included in the study because they comply with medication. 
Table 1.     physicians responses for 179 patients with schizophrenia 
Questions: 
A. Do you suspect that your patient doesn’t comply with medication because he is not 
convinced that he is sick? 
B. Do you think that your patient isn’t compliant with medications because he seeks an 
alternative spiritual 
Medication? 
C. Do you think that your patient has partial compliance because he doesn’t have enough idea 
about his illness? 
D. Do you think that your patient has partial compliance because he doesn’t have knowledge 
about the prescribed                        medications? 
E. Do you think that your patient is partially compliant because he was incapable of noticing 
deterioration in his 
health after omitting the treatment? 
F. Does your patient suffer from problems of cognitive dysfunction that is affecting his daily 
compliance with his 
medications? 
G. Do you think that your patient has partial compliance because of the non availability of, or 
medicine's high cost? 
H. Do you think that your patient has partial compliance because of the long period of taking 
medicine? 
I.  Do you think that your patient has stopped taking medication because of the patient’s 
dissatisfaction and upset of 
Response or expectation of cure? 
J. When your patient felt better and symptoms disappeared, did they at any time think that the 
medication was not necessary and stopped taking it? 
K. Do you suspect that your patient has forgotten to take the prescribed medication in the past 
month  and nobody 
reminded him to take medicine? 
 
Yes n (%) 
144(80.4) 
 
116 (64.8) 
 
 
134 (79.9) 
 
132 (73.7) 
 
116 (64.8) 
 
 
85 ( 47.5) 
 
113 (63.1) 
 
109 (60.9) 
 
68 (38.0) 
 
72 (40.2) 
 
133 (74.3) 
Factors contributing to partial compliance 
Patient-related factors possibly contributing to partial compliance(Table 2), denial of 
illness or patients dissatisfaction of illness (question A)were the most important problems 
(80.4%), followed by inadequate knowledge about illness, and medication 79.9% and 73.7% 
respectively ( question C and D). A total of 74.3% of patients needed someone to remind 
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them to take their medication (question K).The psychiatrists reported that 64.8% of patients 
had anxiety about side-effects(question E) and other  problems such as cognitive dysfunction 
and medication addiction (question F). Cost and availability of medicine were assumed in 
63.1% of the patients (question G), followed by duration and complexity of regimen 60.9% 
(question H). Another factor related to partial compliance was satisfaction of patients with 
other ways for treatment which we called as paramedical or spiritual treatment question B 
(64.8%). The psychiatrists also reported that 40.2% of the patients who stopped taking 
medication after the disappearance of symptoms and they decide the medication is not 
necessary (question J) followed by dissatisfaction of getting better (question I) 38%. Patients 
who were considered to be partially compliant (question A and C) were statistically 
significant more likely to fall in the ‘yes’ category of questions B and D-K than those who 
were considered to be compliant. 
 
Discussion 
To our knowledge this is one of the largest studies among psychiatrists to assess the 
medication compliance of their patients with schizophrenia (Rummel-Kluge et al., 2008). 
Almost 12 psychiatrists and 35 RN assessed the compliance of 200 patients with 
schizophrenia. The fact that patients having compliance problems might appear high but they 
do not seem to represent an overestimation because physicians tend to overestimate 
compliance of their own patients. Difficulties with medication compliance are considered to 
be one of the most important risk factors for relapse and rehospitalization among patients 
with schizophrenia and to cause approximately 40-50%of relapse (Weiden, 1997). Rummel-
Kluge etal. found some differences between psychiatrists working in a hospital assessed their 
patients as having more compliance problems compared to the patients of psychiatrist 
working in private practice. Patients with schizophrenia are usually discharged from hospitals 
to follow-up at their nearest community mental health clinics which focus mainly on 
Table 2. Non/ partial adherence due to 
factors that are patient-related 
• Concerns about the side-effects. 
• Adjustment to suit daily routine. 
• Misunderstanding instructions. 
• Concerns about availability. 
• Concerns about cost. 
• Duration and complexity of regimen. 
• Cognitive dysfunction. 
• Lack of support. 
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pharmacotherapy, with little psychosocial support services owing to lack of human and 
material resources (Maidment et al., 2002). Rummel-Kluge etal. study found possible reasons 
for the differences in the assessments of schizophrenic patients by hospital physicians and 
psychiatrists in private practice. Hospital physicians are confronted with readmissions due to 
relapses more than psychiatrists in private practice.  
 There are several strategies that consider the factors derived from questions and 
contribute to partial compliance, appear promising to improve compliance. First, making 
regular reminders via mail, email or telephone, telephone reminders by families or counseling 
can be helpful in assisting patients with mental disorders to adjust medication timing 
(Rummel-Kluge et al., 2008). The figure in this study shows that 74.3% of patients needed 
someone to remind them to take their medication. Second, Explaining the benefits and 
hazards of treatment option and take into account the patients’ preference, Lack of 
insight/denial of illness contributed to a 5.2-times increase in the risk relapse (Kazadi et al., 
2003). Patients’ understanding of their conditions and their need to treatment is positively 
related to adherence. This studyshowsthat 74.9% of the patients needed to know information 
about their disease and 80.4% of patient’s denial his illness. Low insight may be linked to 
poorer cognitive function and one study suggest that during the first year of treatment, 
patients with poorer premorbid cognitive functioning are more likely to discontinue 
(Robinson et al., 2002). It is possible that the lack of insight in this population might be 
related to lower level of formal education and lack of understanding of mental illness (Stover 
et al., 2008). Psychosocial interventions such as psychoeducation were shown to reduce 
rehospitalization, the lack of insight into the illness and into the need for prophylactic 
medication for relapse prevention. Third, considering adherence aids such as medication 
boxes and alarm and minimize adverse effects, medication side-effects and complex 
regimens; in which this study shows that 64.8% of the patients fear from deterioration in their 
health and 60.9% of them are depressed of the long and complexity of regimens. Patients 
who default on their treatment have said that treatment side-effects (Maguire et al., 2002), 
together with complex costly regimens and durations (Mitchell et al., 2007) are the main 
reasons for their poor adherence because most of them do not feel involved in treatment- 
decision and state that they take medication only because they are told to (Gray et al., 2005). 
 Recent data suggest that patients with schizophrenia participating in research are able 
to understand and retain consent information (Caepenter, 1999). Patients typically leave the 
clinic with a poor understanding of the rational for therapy (Mitchell et al., 2007).Gray etal 
report that most of the participants prescribed antipsychotics did not feel of being  involved in 
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treatment decisions and had not been given written information about their treatment, warned 
about side-effects or offered non-pharmacological alternatives. The more information that is 
given, the better adherence is (Maidment et al., 2002). Taking one daily dosage or 
monotherapy and the use of ‘dosette boxes’, where medication can be kept in daily order for 
7 days (Rummel-Kluge et al., 2008) reduces adherence relapse. So equally regimens that 
require disruption to lifestyle, or special techniques or arrangements are less welcome by 
patients (Mitchell et al., 2007).Thus the patient is not always acting irrationally if they 
attempt to allow for adverse effects or minimize stigma by adjusting doses or times of 
administration (Lambert et al., 2004). Another strategy which improves compliance is: 
establishing a therapeutic relationship and trust. Perkins (2002) reviewed article published up 
to December 2002 correlates poor adherence included patients beliefs about their illness and 
the benefits of treatment (insight into illness, belief that the medication can ameliorate 
symptoms), perceived cost of treatment (medication side effects), and barriers to treatment 
(ease of access to treatment, degree of family or social support). The figures in this study 
show that 80.4% of the patients are not convinced that they are sick. The importance of good 
communication between patient and health professional is increasingly acknowledged in 
relation to adherence (Stevenson et al., 2005). At its essence this means forging a 
jointtherapeutic agreement with full patient involvement, for example discuss mental health 
issues with a doctor, is predicted largely by the perceived helpfulness of and trust in that 
doctor (Mitchell et al., 2007). Other process of making a joint therapeutic plan is often 
abbreviated.                                                                                                                                                       
Conclusion 
Strategies to improve partially compliant patients with antipsychotic drug are needed. 
The importance of good communication between patients and health professional is 
increasingly acknowledged in relation to adherence. Poor adherence owing to lack of insight, 
medication side-effects, complex regimen and lack of sufficient information about disease 
were the most likely factors which increase the relapse in patients with schizophrenia. 
Limitations 
Small sample size might have limited our ability to detect statistically meaningful 
differences. In any retrospective study design, some data might not have been recorded in 
case notes and patients might have been erroneously included or excluded. Another limitation 
is that the questions focused on partial compliance which might have increased the number of 
patients being considered partially compliant.    
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